I was pointed to this article earlier today, where a blogger complains about the coverage the New York Times gave to one of the highest-paid CEOs in its review of the the Equilar Top 200 Highest Paid CEO Rankings. The coverage for transgender woman Martine Rothblatt, was as follows.

The highest-paid woman on the Equilar list was born a man.

Martine Rothblatt, born Martin Rothblatt, was the married father of four children and started Sirius Satellite Radio, now SiriusXM, before undergoing gender reassignment surgery in 1994. After one of her children was diagnosed with a disease, she founded United Therapeutics in 1996 and helped develop a drug to treat the illness. Last year, she was paid $38 million in compensation, most of it in stock options, putting her at No. 10 on the list. She declined to be interviewed.

“Her equity grant is awarded based on company performance, the best way to be aligned with the interests of shareholders,” said Andrew Fisher, deputy general counsel at the company. Its stock price more than doubled last year, largely because it received Food and Drug Administration approval for a new drug, Orenitram.

I noticed the same thing the DailyDot focused on – she was the ONLY person discussed where it is mentioned “she declined to be interviewed.” That phrase is usually a “trigger phrase” used by breathless news reporters who are chasing a scandal. However, I still am on the fence about whether or not it’s anti-transgender bias, or just a hamhanded way for a reporter to include a “personal note” connected to a CEO (even though that really shouldn’t be a personal note, in a perfect world.)